| AiTan (rivoceranib) / HLB Bio Group |
ChiCTR-OPN-16009458: A clinical research of Apatinib unite chemotherapy in second-line treatment of advanced lung cancer, gastric cancer and colorectal cancer |
|
|
| Recruiting | 4 | 90 | | combination of apatinib based on the second-line chemotherapy | Suzhou City Hospital; Suzhou City Hospital, self-financing | cancer | | | | |
ChiCTR-OPN-16009457: A exploratory controlled clinical study of Apatinib combined TACE in treating advanced hepatocellular carcinoma |
|
|
| Recruiting | 4 | 100 | | Apatinib Mesylate Tablets | the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing | cancer | | | | |
ChiCTR-OPC-17011020: A clinical research of Apatinib in the treatment of advanced refractory non-small cell lung cancer |
|
|
| Recruiting | 4 | 30 | | Apatinib | 101th Hospital of PLA; Level of the institution：, Self-raised funds | NSCLC | | | | |
ChiCTR1800015701: A Real-world Study of Apatinib in the treatment for Inoperable or advanced gastric cancer in Shandong |
|
|
| Recruiting | 4 | 1000 | | apatinib | Shandong Cancer Hospital; Jiangsu Hengrui Medicine Co., Ltd., self-financing | Inoperable or advanced gastric cancer | | | | |
ChiCTR2000040387: A real-world study of apatinib combined with TACE in patients with advanced liver cancer |
|
|
| Recruiting | 4 | 300 | | apatinib | The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, self-financing | Intermediate to advanced hepatocellular carcinoma | | | | |
ChiCTR2100041973: A prospective, open, single-arm, single-center phase II clinical study of carrelizumab combined with apatinib and tigio capsules in the second-line treatment of patients with metastatic cholangiocarcinoma |
|
|
| Recruiting | 4 | 30 | | Patients with metastatic biliary tract cancer (including gallbladder cancer and cholangiocarcinoma) who have undergone first-line treatment | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-funded | Cholangiocarcinoma | | | | |
ChiCTR2100044694: The prognostic value of PD-L1 in the treatment of advanced hepatocellular carcinoma with combination of apatinib and karelizumab |
|
|
| Recruiting | 4 | 30 | | They were treated with apatinib and karelizumab combined system, without TACE and other local treatment ;The patients with HCC were treated with apatinib and karelizumab combined with TACE | Shandong Provincial Hospital; Shandong Provincial Hospital, China Health Promotion Foundation | Advanced hepatocellular carcinoma | | | | |
ChiCTR-OPN-15006601: A prospectiv, multi-center, non-intervention study of Apatinib in the treatment of advanced gastric cancer |
|
|
| Recruiting | 4 | 230 | | apatinib | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing | advanced gastric cancer | | | | |
ChiCTR-OPN-15007034: A prospective, multi-center study of Apatinib in the treatment of advanced cancer |
|
|
| Recruiting | 4 | 100 | | none | The Second Affiliated Hospital of Soochow University; the Second Affiliated Hospital of Soochow University, self-financing | cancer | | | | |
ChiCTR-IPR-15006993: Apatinib as Maintenance Therapy After First-line Chemotherapy (DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer |
|
|
| Not yet recruiting | 4 | 48 | | Apatinib Mesylate Tablets 500 mg qd p.o. ;Best Support Care | Fourth Hospital, Hebei Medical University; Hebei Medical University affiliated Fourth Hospital, self-raise | Gastric Cancer | | | | |
ChiCTR-OPC-16010108: The clinical study of Apatinib mesylate combined with Temozolomide in treating patients with recurrent high-grade glioma |
|
|
| Recruiting | 4 | 40 | | Apatinib Mesylate Tablets | the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing | cancer | | | | |
ChiCTR-OPN-15007443: A prospectiv, single-arm study of Apatinib unite docetaxel in the treatment of advanced squamous cell carcinoma of the lung |
|
|
| Recruiting | 4 | 60 | | Apatinib unite docetaxel | the second people's hospital of lianyungang; The Second People's Hospital of Lianyungang, self-financing | advanced squamous cell carcinoma of the lung | | | | |
ChiCTR-OPC-16008295: A observational clinical study of Apatinib combined chemotherapy in the treatment of gastric cancer with AFP positive |
|
|
| Not yet recruiting | 4 | 16 | | combined chemotherapy | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing | advanced gastric cancer | | | | |
ChiCTR-OPC-16008296: A clinical study of Apatinib combined chemotherapy in the treatment of advanced gastric cancer with malignant peritoneal effusion |
|
|
| Not yet recruiting | 4 | 30 | | combined chemotherapy | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing | advanced gastric cancer | | | | |
ChiCTR-IPR-16008335: A clinical study of postoperative adjuvant chemotherapy in the treatment of gastric carcinoma unite Apatinib |
|
|
| Not yet recruiting | 4 | 60 | | combined chemotherapy | The People's Liberation Army 101 Hospital; The People's Liberation Army 101 Hospital, self-financing | gastric cancer | | | | |
ChiCTR-OPC-16009048: Clinical study of Apatinib Mesylate Tablets in the Second-line treatment of Advanced Squamous Cell Lung Cancer |
|
|
| Recruiting | 4 | 30 | | combined S-1 | Anhui Chest Hospital; Anhui Chest Hospital, self-financing | Squamous Cell Lung Cancer | | | | |
ChiCTR-OPC-16007953: Clinical study of apatinib mesylate tablets in the treatment of refractory soft tissue sarcoma |
|
|
| Not yet recruiting | 4 | 30 | | Medical and nursing education for patients with soft tissue sarcoma | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Henry csco- Cancer Research Fund | Refractory soft tissue sarcoma | | | | |
ChiCTR-IPR-15006994: Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells |
|
|
| Not yet recruiting | 4 | 48 | | Apatinib Mesylate Tablets 500 mg qd p.o. ;Best Support Care | Fourth Hospital, Hebei Medical University; Hebei Medical University affiliated Fourth Hospital, self-raise | Gastric Cancer | | | | |
ChiCTR-IPR-17010361: First-line randomized, open, controlled clinical trial of EP regimen with sequential apatinib in patients with extensive stage small cell lung cancer |
|
|
| Not yet recruiting | 4 | 120 | | EP, 80mg/ m D1 cisplatin, etoposide 100mg/ square meters, D1-3, apatinib mesylate tablets: 500 or 750 mg QD Po, D4 to the next cycle of twenty-first days, 4 weeks for 1 cycles, 2 cycles of evaluation time, 6 cycle withdrawal. ;EP, 80mg/ m D1 cisplatin, etoposide 100mg/ square meters, D1-3, cycle of twenty-first days, 4 weeks for 1 cycles, 2 cycles of evaluation time, 6 cycle withdrawal. | The North Hospital of the Affiliated Hospital of Qiingdao University hospital; The North Hospital of the Affiliated Hospital of Qiingdao University hospital, CSCO Fund / Jiangsu Hengrui Medicine Co. Ltd. | extensive stage small cell lung cancer | | | | |
ChiCTR-OPC-16009849: A study to determine the curative effect and mechanism of Apatinib combined with chemotherapy for SD patients with advanced malignant solid tumor |
|
|
| Recruiting | 4 | 100 | | Apatinib Mesylate Tablets | the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing | cancer | | | | |
ChiCTR-OPC-17013834: Clinical study of Apatinib combined with docetaxel as second-line treatment in advanced gastric cancer |
|
|
| Recruiting | 4 | 20 | | Apatinib combined with Docetaxel | Shanxi Tumor Hospital; Shanxi Tumor Hospital, Chinese Anti-Cancer Association- HengRui pharmaceutical innovative medicine clinical research fund | gastric cancer | | | | |
ChiCTR-OPC-17011019: An opening, single arm study of Apatinib in the treatment of advanced hepatocellular carcinoma |
|
|
| Recruiting | 4 | 60 | | Apatinib | Huai'an First People's Hospital, Nanjing Medical University; Huai'an First People's Hospital, Nanjing Medical University, Jiangsu Hengrui Medicine Co., Ltd. | hepatocellular carcinoma | | | | |
ChiCTR-OPC-17011376: The clinical research of Apatinib for the treatment of advanced non-small cell lung cancer |
|
|
| Recruiting | 4 | 30 | | Apatinib | the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing | cancer | | | | |
ChiCTR-OPC-17011378: The clinical observational study of Apatinib 425mg Joint docetaxel for the second-line treatment of advanced lung squamous carcinoma |
|
|
| Recruiting | 4 | 30 | | Apatinib +docetaxel | the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing | cancer | | | | |
ChiCTR-OPC-16008637: A Study of Second-line Treatment With Apatinib and S-1 in Advanced Hepatocellular Carcinoma Patients |
|
|
| Recruiting | 4 | 120 | | Apatinib 500mg/day ;Apatinib 750mg/day ;S-1 | the First Affiliated Hospital of Zhengzhou University; the First Affiliated Hospital of Zhengzhou University, CSCO- Henry Cancer Research Fund | Advanced Hepatocellular | | | | |
ChiCTR-OPC-16009894: Exploratory clinical study of apatinib mesylate tablets in the treatment of EGFR negative patients with non squamous non-small cell lung cancer. |
|
|
| Recruiting | 4 | 40 | | Apatinib + cisplatin + docetaxel ;cisplatin + docetaxel | The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, raise independently | lung cancer | | | | |
ChiCTR-OPC-17011822: A clinical study of Apatinib combined TACE in treating intermediate and advanced hepatocellular carcinoma |
|
|
| Recruiting | 4 | 100 | | Apatinib+TACE | the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing | cancer | | | | |
ChiCTR-OPC-17010714: Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy in locally advanced colorectal cancer clinical research |
|
|
| Recruiting | 4 | 60 | | Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy | Tianjin people's hospital; Tianjin people's hospital, Jiang Su Heng Rui medicine. co.LTD | Colorectal cancer | | | | |
ChiCTR1800015202: Clinical study of Apatinib combined with chemotherapy or single Drug for second-line treatment failure in advanced ovarian cancer |
|
|
| Not yet recruiting | 4 | 30 | | Apatinib combined with conventional chemotherapy regimen | Yibin second people's Hospital; Yibin second people's Hospital, Self financing | ovarian cancer | | | | |
ChiCTR-OIC-16008894: Taxanes combined with Apatinib mesylate in the treatment for patients with advanced breast cancer: an open-label, single-arm, single-center clinical research |
|
|
| Recruiting | 4 | 30 | | Apatinib 500mg/day | The First Hospital of Lanzhou Uiversity; The First Hospital of Lanzhou University, self-financing | advanced breast cancer | | | | |
ChiCTR-OPC-17011722: An open and one-armed exploration of Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 4 | 80 | | Apatinib+Docetaxel | The First Affiliated Hospital Of Nanchang University; The First Affiliated Hospital Of Nanchang University, self-financing | cancer | | | | |
| Recruiting | 4 | 40 | | Apatinib 250mg/Day | Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, self-financing | Hepatocellular carcinoma | | | | |
ChiCTR-OPN-17013220: An open-label, single-arm, prospective study of TACE combined with apatinib for unresectable liver metastases from colorectal cancer |
|
|
| Recruiting | 4 | 20 | | TACE combined with apatinib | Yueyang Hospital of integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Mesdicne; Yueyang Hospital of integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Mesdicne, self-raised | colorectal liver metastases | | | | |
ChiCTR-OPN-17013304: Clinical study of first-line therapy with Apatinib Mesylate in combination with chemotherapy for EGFR-negative advanced non-small cell lung cancer |
|
|
| Recruiting | 4 | 60 | | Apatinib + Docetaxel + Platinum; Docetaxel + Platinum | 2nd People's Hospital of Fuyang City; 2nd People's Hospital of Fuyang City, self-financing | NSCLC | | | | |
ChiCTR1800020145: Open, single-arm, exploratory study for apatinib mesylate in the treatment of recurrent glioma |
|
|
| Completed | 4 | 32 | | Patients were treated with temozolomide combined with apatinib | Sanbo Brain Hospital, Capital Medical University; Sanbo Brain Hospital, Capital Medical Universit, Jiangsu hengrui pharmaceutical co., LTD | glioma | | | | |
ChiCTR-OPC-17010758: Mesylate apatinib combined with chemotherapy in the treatment of clinical study of osteosarcoma recurrence and metastasis |
|
|
| Recruiting | 4 | 40 | | Apatinib or apatinib + chemotherapy | Xijing Hospital affiliated to The Fourth Military Medical University; Xijing Hospital affiliated to The Fourth Military Medical University, 经费自筹 Self financing | osteosarcoma | | | | |
ChiCTR-OPC-17012186: An prospective, single-arm, multi-center clinical trial of Apatinib combined with capecitabine in the treatment of advanced ovarian cancer |
|
|
| Recruiting | 4 | 30 | | combined Capecitabine | The Second People's Hospital of Hefei; The Second People's Hospital of Hefei, self-financing | Ovarian cancer | | | | |
ChiCTR-OPC-17010671: Clinical study of combined use of apatinib in patients with locally advanced cervical cancer during concurrent radiotherapy and chemotherapy |
|
|
| Not yet recruiting | 4 | 30 | | Apatinib + cisplatin + radiotherapy | Qinghai Red Cross Hospital; Qinghai Red Cross Hospital, Self financing | locally advanced cervical carcinoma | | | | |
ChiCTR-OPN-17011652: A clinical study of recurrent ovarian ovarian cancer in the treatment of platinum resistance in apatinib tablet |
|
|
| Not yet recruiting | 4 | 280 | | Apatinib + chemotherapy ;Pure chemotherapy | Xijing Hospital affiliated to The Fourth Military Medical University; Xijing Hospital affiliated to The Fourth Military Medical University, Self financing | Late-stage platinum resistant ovarian cancer | | | | |
ChiCTR-OPC-17010572: Clinical study of adenocarcinoma with apatinib mesylate tablets combined with chemotherapy as second-line treatment of advanced gastric cancer or gastric esophagus |
|
|
| Not yet recruiting | 4 | 100 | | limit into the grop and the ruled out | Yangzhong People's Hospital; Yangzhong People's Hospital, self-raised | gastric cancer | | | | |
ChiCTR1800015308: A multi-center single arm study of FOLFIRI combined with Apatinib on the treatment of non resectable metastatic colorectal cancer |
|
|
| Recruiting | 4 | 40 | | FOLFIRI combined with apatinib | Shanxi Tumor Hospital; Shanxi Tumor Hospital, Chinese Anti-Cancer Association- HengRui pharmaceutical innovative medicine clinical research fund | advanced colorectal cancer | | | | |
ChiCTR1800015494: Clinical study of apatinib mesylate tablets combined with chemotherapy in the treatment of platinum sensitive recurrent ovarian cancer |
|
|
| Recruiting | 4 | 60 | | To use Apatinib mesylate tablets，and Paclitaxel and carboplatin ;Only use Paclitaxel and carboplatin | Jiangsu Cancer Hospital; Jiangsu Hengrui pharmaceutical Limited by Share Ltd, Self financing | Oophoroma | | | | |
ChiCTR-OPC-17011248: The observation of clinical effect on Apatinib treatment of advanced malignant tumor by the evaluation of Peripheral blood circulating tumor cells |
|
|
| Recruiting | 4 | 20 | | Apatinib | Sir Run Run Shaw Hospital School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital School of mMedicine, Zhejiang University, self-financing | malignant tumor | | | | |
ChiCTR1900024189: Clinical Study for Sequential Chemotherapy with Apatinib in Patients with Non-small Cell Lung Cancer |
|
|
| Recruiting | 4 | 60 | | Apatinib Combined with Docetaxel ;Docetaxel | Shanxi Provincial Hospital of Traditional Chinese Medicine; Shanxi Provincial Hospital of Traditional Chinese Medicine, csco hengrui fund | lung cancer | | | | |
ChiCTR-IPC-17012721: For the prospective study of apatinib mesylate, single arm, open and exploratory tablets in the treatment of muscle invasive urothelial carcinoma patients |
|
|
| Recruiting | 4 | 20 | | Apatinib + gemcitabine + cisplatin ;gemcitabine + cisplatin | Tangdu Hospital of Air Force Military Medical University; Tangdu Hospital of Air Force Military Medical University, Self financing | Bladder cancer | | | | |
ChiCTR1800016882: Esophageal Artery Perfusion Chemotherapy Combined with Apatinib in the Treatment of Advancand Esophageal Carcinoma with Failure of Radiochemotherapy: A Prospective, Exploratory, Open, Single-center, One-arm Clinical Trial |
|
|
| Recruiting | 4 | 60 | | Esophageal cancer infusion chemotherapy combined with apatinib | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-financing | Esophageal Carcinoma | | | | |
ChiCTR-OPC-17013445: An investigation of effect and safety of Apatinib in the treatment of advanced NSCLC |
|
|
| Not yet recruiting | 4 | 100 | | Apatinib | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-financing | NSCLC | | | | |
ChiCTR1800016391: A clinical study of apatinib and cisplatin with concurrent radiotherapy for treatment of cervical cancer |
|
|
| Recruiting | 4 | 218 | | apatinib+cisplatin+radiotherapy ;cisplatin+radiotherapy | The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Self financing | cervical cancer | | | | |
ChiCTR1800020105: Clinical study for second-line treatment of apatinib mesylate tablets in patients with advanced EGFR wild-type, non-squamous and non-small-cell lung cancer |
|
|
| Completed | 4 | 30 | | Docetaxel 60mg/m2, i.v. repeat three weeks a cycle, 4 - 6 courses; apatinib 250mg, p.o. qd, 28 cycles | Nanjing Military Region General Hospital; Nanjing Military Region General Hospital, self-raised funds | EGFR wild type, scale, non-small cell lung cancer | | | | |
ChiCTR1800017323: A phase II study of apatinib combined with with XELOX regimen in the treatment of locally advanced gastric cancer |
|
|
| Recruiting | 4 | 20 | | apatinib combined with with XELOX regimen | The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital); The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital), Self financing | gastric cancer | | | | |
ChiCTR1800017332: A pilot study for Apatinib Mesylate combined with Gifitinib in First-line treatment of Lung Adenocarcinoma with malignant pleural effusion or pericardial effusion |
|
|
| Recruiting | 4 | 10 | | Apatinib mesylate tablets combined with gefitinib | Jiangsu Subei People's Hospital; Jiangsu Subei People's Hospital, Self-financing | Carcinoma of the lungs | | | | |
ChiCTR1800014504: Non-intervention study of apatinib combined with capecitabine versus capecitabine in the treatment of advanced metastatic colorectal cancer |
|
|
| Not yet recruiting | 4 | 138 | | Apatinib + capecitabine ;capecitabine | Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College, Self financing | Metastatic colorectal cancer | | | | |
ChiCTR1800017837: A single-arm, prospective Clinical Study of apatinib combined with SOX protocol for first-line treatment of advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 30 | | Apatinib combined with SOX | Gansu Province Cancer Hospital; Gansu Province Cancer Hospital, raise independently | not operable, recurrent or metastatic advanced gastric or gastric esophageal junction adenocarcinoma | | | | |
ChiCTR1900024399: The Real World Study of Apatinib for Postoperative Adjuvant Therapy of Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 4 | 300 | | Apatinib | Qinzhou First People's Hospital; Qinzhou First People's Hospital, Self-financing | Liver cancer | | | | |
ChiCTR-OPN-17011968: Apatinib mesylate tablets combined with docetaxel and nedaplatin in the treatment of advanced ovarian cancer by observational clinical study of postoperative patients |
|
|
| Recruiting | 4 | 40 | | Apatinib + docetaxel plus nedaplatin; docetaxel plus nedaplatin | Tumor Hospital of Shaanxi province; Level of the institution：, Self financing | ovarian cancer | | | | |
ChiCTR-IPR-17012667: An prospective, open-label, random and control clinical trail of Apatinib combined with TACE contrast to the simple TACE in the treatment of recurrent hepatocellular carcinoma (HCC) |
|
|
| Recruiting | 4 | 40 | | Apatinib Tablets orally ;TACE | Xinqiao Hospital, Chongqing; Xinqiao Hospital, Chong qing, self financing | Liver cancer | | | | |
ChiCTR-OPC-17010708: In the second or higher standard chemotherapy failure in patients with advanced colorectal cancer using mesylate apatinib tablets multicenter, open, single arm and exploratory research |
|
|
| Recruiting | 4 | 54 | | Restricted entry | The first Affiliated Hospita of Nanjing Medical University; The first Affiliated Hospita of Nanjing Medical University, self-raised | Colon cancer | | | | |
ChiCTR-OPC-17012676: An prospective, single center, open, stage II clinical trail of Apatinib for treatment of locally advanced or metastatic thyroid undifferentiated thyroid cancer |
|
|
| Recruiting | 4 | 10 | | Apatinib | Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds | Undifferentiated thyroid carcinoma | | | | |
ChiCTR1800018546: A clinical study for Neoadjuvant Chemotherapy using apatinib plus L-OHP and capecitabine in local advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 48 | | Apatinib combined with XELOX | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University Intervention Department, Self raise independently | Locally advanced gastric cancer | | | | |
ChiCTR-OPC-17013262: Clinical study of Apatinib combination with SOX as First line treatment in patients with adenocarcinoma of the Stomach or Gastroesophageal Junction |
|
|
| Recruiting | 4 | 50 | | Apatinib combined with SOX | Shanxi Tumor Hospital; Shanxi Tumor Hospital, No | gastric cancer | | | | |
ChiCTR-OPC-17012933: Study of using second-line chemotherapy plus Apatinib in local recurrence or metastatic breast cancer |
|
|
| Recruiting | 4 | 80 | | Apatinib+Second-line chemotherapy | The first Affiliated Hospital of Wenzhou Medical University; The first Affiliated Hospital of Wenzhou Medical University, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds | Breast Cancer | | | | |
ChiCTR-OPC-17012473: A prospective, non-intervention real world study of Apatinib in the treatment of advanced lungsquamous carcinoma |
|
|
| Recruiting | 4 | 88 | | apatinib | The Second People's Hospital of Yibin; The Second People's Hospital of Yibin, Self-financing | Lung Cancer | | | | |
ChiCTR-OPC-17013162: Phase II multi-center trial of Apatinib combined with EGFR-TKIs therapy in slow progress and T790M of advanced non-small cell lung cancer after treatment with first-generation EGFR-TKIs |
|
|
| Recruiting | 4 | 52 | | Apatinib+EGFR-TKI | Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds | non-small cell lung cancer | | | | |
ChiCTR-OPC-17013522: An open-label,single-arm trial of HIPEC combined with Apatinib in patients with advanced peritoneal implantation tumor |
|
|
| Suspended | 4 | 30 | | Apatinib+HIPEC | Hangzhou Cancer Hospital; Hangzhou Cancer Hospital, self financing | peritoneal implantation tumor | | | | |
| Recruiting | 4 | 60 | | Apatinib+ RFA ;RFA | Sir Run Run Shaw Hospital; Sir Run Run Shaw Hospital, self-financing | Hepatocellular Carcinoma | | | | |
ChiCTR-OPC-17013602: Clinical study of apatinib combined with oxaliplatin in the treatment of platinum - resistant recurrent ovarian cancer . |
|
|
| Not yet recruiting | 4 | 20 | | Apatinib Tablets orally | Xin qiao Hospital, Chong qing; Xinqiao Hospital, Chong qing, self financing | Ovarian cancer | | | | |
ChiCTR-IPR-17010776: A exploratory Study of Apatinib and Gefitinib First-line treatment in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations |
|
|
| Not yet recruiting | 4 | 60 | | Gefitinib 250mgpo, qd and Apatinib, 250 mg Po qd ;Gefitinib 250mg po qd | First Affiliated Hospital of Third Military Medical University; First Affiliated Hospital of Third Military Medical University, Hengrui pharmaceutical co., LTD. offers research funding | NSCLC | | | | |
ChiCTR1800014964: A prospective ,single arm, open study of Mesylate Apatinib combined with FOLFOX in the treatment of advanced colorectal cancer |
|
|
| Not yet recruiting | 4 | 40 | | Mesylate Apatinib | Affiliated Tumor Hospital of GuangXi Medical University; Level of the institution：, self-raised | colorectal cancer | | | | |
ChiCTR1800015196: The prospective and open phase II clinical trial of whole brain radiotherapy combined with anti-angiogenesis therapy for wild-type EGFR non-squamous NSCLC with multiple brain metastases |
|
|
| Not yet recruiting | 4 | 40 | | Apatinib combined with radiotherapy | Yunnan Cancer Hospital; Yunnan Cancer Hospital, Cancer Foundation of China, Fund of Beijing Marathon of Hope | EGFR wild-type non-squamous NSCLC with multiple brain metastases | | | | |
ChiCTR1800016448: A clinical study of Apatinib mesylate tablets combined with radiotherapy in the treatment of patients with advanced hepatocellular carcinoma (HCC) |
|
|
| Recruiting | 4 | 60 | | Apatinib mesylate tablets ＋ radiotherapy ;radiotherapy | Tangdu Hospital of Fourth Medical University of Chinese PLA.; Level of the institution：, Self-raised funds | advanced HCC | | | | |
ChiCTR1800018500: One-arm, single-center, open-label clinical study of lapatinib mesylate combined with docetaxel in the treatment of lung adenocarcinoma with no driver gene mutation |
|
|
| Not yet recruiting | 4 | 20 | | Apatinib combined with docetaxel | The People's Hospital of Tongliang District, Chongqing; The People's Hospital of Tongliang District.Chongqing City, Jiangsu hengrui pharmaceutical co. LTD | Lung adenocarcinoma without driver gene mutation | | | | |
| Recruiting | 4 | 30 | | Apatinib 250 mg qd, po; standard chemotherapy | Daping Hospital; Daping Hospital, self-financing | cervical cancer | | | | |
| Recruiting | 4 | 30 | | Apatinib, 250 mg qd, po; standard chemotherapy | Daping Hospital; Daping Hospital, self-financing | ovarian cancer | | | | |
| Recruiting | 4 | 40 | | Apatinib, 250 mg Po qd, paclitaxel or docetaxel combined with platinum standard chemotherapy regimens, q21d, 2 to 6 cycles of chemotherapy ;paclitaxel or docetaxel combined with platinum standard chemotherapy regimens, | Daping Hospital; None, self-financing | esophageal cancer | | | | |
ChiCTR-IPR-17010456: Apatinib and radiotherapy Compared with zoledronic acid and radiotherapy Treatment in Patients With bone metastases of Malignant tumor |
|
|
| Recruiting | 4 | 60 | | Apatinib, 250 mg po, qd, Local radiotherapy ;zoledronic acid: 4 mg, iv, Every 4 weeks; Local radiotherapy | Da Hospital; Da Hospital, self-financing | cancer | | | | |
ChiCTR-OPC-17013964: A Non-randomized, Open-label, Prospective, Multicenter Study of Apatinib Mesylate Tablet as Second-line and Later Therapy in Patients With Extensive Stage Small Cell Lung Cancer |
|
|
| Completed | 4 | 60 | | Restricted entry | Affiliated Hospital of Jiangnan University and Fourth People's Hospital of Wuxi; Affiliated Hospital of Jiangnan University and Fourth People's Hospital of Wuxi, Self financing | Small Cell Lung Cancer | | | | |
ChiCTR1800014428: Apatinib mesylate tablets combined with gefitinib in the treatment of non-small cell lung cancer with gefitinib T790M mutation, single center, open, single arm clinical study |
|
|
| Recruiting | 4 | 30 | | apatinib | Xijing Hospital; Xijing Hospital, Self financing | lung cancer | | | | |
ChiCTR1800014313: A real world study of sequential study of SBRT sequential therapy with apatinib mesylate in the treatment of advanced liver cancer |
|
|
| Not yet recruiting | 4 | 30 | | SBRT followed by apatinib ;apatinib | Sichuan Provincial People's Hospital; Sichuan Provincial People’s Hospital, Jiangsu Hengrui Medicine Co., Ltd funded | liver cancer | | | | |
ChiCTR1800017789: A real world major data study for Apatinib in the treatment of advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 1000 | | Apatinib | Zhejiang Provincial Hospital of TCM, Zhejiang Cancer Hospital; Zhejiang Provincial Hospital of TCM, self-financing | advanced gastric cancer | | | | |
ChiCTR1900021506: Therapeutic effect of apatinib monotherapy on recurrence and persistent cervical squamous cell carcinoma due to failure of chemoradiotherapy or other targeted therapy and correlation research between the efficacy of apatinib and the angiogenesis immune response subtype gene |
|
|
| Not yet recruiting | 4 | 40 | | Apatinib monotherapy | Chongqing Cancer Hospital; Chongqing Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Cervical squamous cell carcinoma | | | | |
ChiCTR1900020825: One-arm, open clinical study of apatinib mesylate combined with EGFR-TKI in the treatment of advanced non-squamous cell lung cancer patients with EGFR gene mutation |
|
|
| Not yet recruiting | 4 | 120 | | apatinib combined with EGFR-TKI | Affiliated Hospital of Inner Mongolia Medical University; Affiliated Hospital of Inner Mongolia Medical University, Self financing | lung cancer | | | | |
ChiCTR1800015057: Third-line therapy with apatinib in metastatic colorectal cancer: individualized dose adjustment based on plasma concentration and adverse reactions |
|
|
| Recruiting | 4 | 36 | | apatinib | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self financing | Metastatic colorectal cancer | | | | |
ChiCTR1800015920: Efficacy and safety of apatinib combined with pemetrexed plus platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer |
|
|
| Completed | 4 | 40 | | apatinib 250mg Qd combined with chemotherapy ;apatinib 500mg Qd combined with chemotherapy | National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Foundation of China, Terry Fox Run, Marathon of Hope | Non-squamous non-small cell lung cancer | | | | |
ChiCTR1800015764: Single arm, open, prospective study low dose of Apatinib in the treatment of primary and recurrent high grade gliomas |
|
|
| Recruiting | 4 | 30 | | apatinib + Temozolomide + radiotherapy | Gansu Province Cancer Hospital; Gansu Province Cancer Hospital, raise independently | primary and recurrent high grade gliomas | | | | |
| Recruiting | 4 | 30 | | Apatinib+ RFA | Sir Run Run Shaw Hospital; Sir Run Run Shaw Hospital, self-financing | lung cancer | | | | |
ChiCTR1800016501: Apatinib combined with pemetrexed plus cisplatin as the first-line treatment of patients with negative diver gene advanced non-squamous non-small cell lung cancer: a single - center and single - arm clinical study |
|
|
| Recruiting | 4 | 20 | | apatinib | Affiliated Hospital of Shandong Academy of Medical Sciences; Affiliated Hospital of Shandong Academy of Medical Sciences, self financing | negative diver gene advanced non-squamous non-small cell lung cancer | | | | |
ChiCTR1800017225: Clinical study of apatinib mesylate combined with paclitaxel in second-line and second-line maintenance of advanced gastric cancer |
|
|
| Recruiting | 4 | 60 | | apatinib mesylate combined with paclitaxel | Jiangxi Tumor Hospital; Jiangxi Tumor Hospital, Jiangsu hengrui pharmaceutical co. LTD | gastric cancer | | | | |
ChiCTR1900020699: Randomized controlled prospective trial for apatinib mesylate combined with TACE in the treatment of advanced hepatocellular carcinoma |
|
|
| Recruiting | 4 | 120 | | TACE+Oral administration of apatinib at 500mg/ day ;Only TACE | The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, At his own expense | liver cancer | | | | |
ChiCTR-OPN-16008694: Clinical study of Apatinib Mesylate Tablets unite Docetaxel in the Second-line treatment of EGFR Wild-type Advanced Non-Squamous Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 4 | 55 | | Apatinib and docetaxel | Huizhou People's Hospital; Huizhou People's Hospital, self-financing | EGFR Wild-type Advanced Non-Squamous Non-Small Cell Lung Cancer | | | | |
ChiCTR1800017424: Mesylate tablets of apatinib as first-line treatment of metastatic soft tissue sarcoma, randomized, crossover, multi center clinical study |
|
|
| Recruiting | 4 | 80 | | IFO+EPI regimen ;Pan apatinib scheme | General Hospital of Shenyang Military Area Command; General Hospital of Shenyang Military Area Command, Self-raising | metastatic soft tissue sarcoma | | | | |
ChiCTR1800016529: A prospective, open label, randomized, controlled trial for evaluation of the safety and efficacy of Apatinib mesylate tablets combined with docetaxel in the treatment of metastatic breast cancer |
|
|
| Recruiting | 4 | 130 | | Apatinib Mesylate Tablets versus Docetaxel combined with Docetaxel | Breast center of Jiangxi Tumor Hospital; Level of the institution：, Self financing | breast cancer | | | | |
ChiCTR1800018642: An exploration of Apatinib Plus IP solution as 2nd Line Treatment in Patients With Small Cell Lung Cancer |
|
|
| Recruiting | 4 | 30 | | apatinib mesylate combined with IP chemotherapy | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | Non-small Cell Lung Cancer | | | | |
ChiCTR1800017537: One-arm, single-center, open-label clinical study of concurrent chemoradiotherapy combined with adjuvant chemotherapy and antiangiogenic therapy for advanced malignant tumors |
|
|
| Not yet recruiting | 4 | 30 | | Apatinib monotherapy or apatinib combined with other drugs | Chongqing Cancer Hospital; ChongQing Cancer Hospital, Jiangsu hengrui pharmaceutical co. LTD | advanced malignant solid tumors | | | | |
ChiCTR1800017333: Therapeutic effect of transcatheter arterial chemoembolization(TACE) combined with anti-angiogenesis therapy on patients with liver cancer |
|
|
| Not yet recruiting | 4 | 20 | | TACE+Apatinib | The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hengrui Pharmaceutical co. LTD | Hepatocellular carcinoma | | | | |
ChiCTR1800017375: Observational clinical study of apatinib for advanced malignant solid tumors |
|
|
| Recruiting | 4 | 30 | | Apatinib monotherapy or apatinib combined with other drugs | The First Hospital Affiliated to AMU/Southwest Hospital; The First Hospital Affiliated to AMU/Southwest Hospital, Jiangsu hengrui pharmaceutical co. LTD. | advanced malignant solid tumors | | | | |
ChiCTR1800017511: Study on the maintenance of apatinib and the administration of apatinib in patients with primary liver cancer after TACE treatment |
|
|
| Recruiting | 4 | 40 | | Apatinib monotherapy for maintenance after TACE treatment | Chongqing Cancer Hospital; Chongqing Cancer Hospital, Jiangsu hengrui pharmaceutical co. LTD | Hepatocellular carcinoma that cannot be resected or relapses after resection | | | | |
ChiCTR1800014477: Mesylate apatinib as monotherapy or in combination with capecitabine in the treatment of advanced breast cancer multicenter, open, single arm clinical study |
|
|
| Not yet recruiting | 4 | 96 | | apatinib or apatinib plus capecitabine | Sui'ning Central Hospital; Sui'ning Central Hospital, Self financing | advanced breast cancer | | | | |
ChiCTR1800017494: A prospective, open-label, one-arm clinical study of pemetrexed in combination with platinum-based regimens in patients with advanced non-squamous non-small cell lung cancer treated with apatinib after 4-6 cycles of chemotherapy |
|
|
| Not yet recruiting | 4 | 20 | | Apatinib monotherapy for maintenance treatment | Xinqiao Hospital, Army Medical University; XinQiao Hospital, Amy Medical University, Jiangsu hengrui pharmaceutical co. LTD | Non-scale non-small cell lung cancer | | | | |
ChiCTR1800017503: Clinical study for effect and safety, as well as prognostic factors analysis of apapitatin mesylate combined with TACE in the treatment of patients with advanced hepatocellular carcinoma |
|
|
| Not yet recruiting | 4 | 40 | | Apatinib monotherapy for maintenance treatment after TACE treatment | Daping Hospital, Army Medical University; DaPing Hospital, Army Medical University, Jiangsu hengrui pharmaceutical co. LTD | Advanced hepatocellular carcinoma | | | | |
ChiCTR1900027247: One-arm clinical study for camrelizumab, apatinib mesylate and TACE in the treatment of advanced hepatocellular carcinoma |
|
|
| Recruiting | 4 | 20 | | camrelizumab, apatinib mesylate and TACE | The First Affiliated Hospital of Suzhou University; The First Affiliated Hospital of Suzhou University, Self financing | Liver cancer | | | | |
